FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Adverse events · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Time to first pulmonary exacerbation · adults with cystic fibrosis and with the F508del/MF genotype
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival · adults and children with cystic fibrosis
1 finding from 1 review
Quality of life: total score · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy as a continuous outcome · adults with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · adults with cancer and depression
It is very uncertain whether antidepressants changes efficacy as a dichotomous outcome compared with placebo (very low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · adults with cancer and depression
It is very uncertain whether antidepressants changes dropouts due to any cause (acceptability) compared with placebo (very low certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations treated… compared with placebo (high certainty).
1 finding from 1 review
Patients with severe exacerbations (requiring hospitalisation or ER visit) · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Asthma control · children and adults with predominantly mild to moderate asthma
1 finding from 1 review
FEV1 % predicted · children and adults with predominantly mild to moderate asthma
1 finding from 1 review
Proportion of participants with one or more serious adverse events due to any cause · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more serious adverse events… compared with placebo (high certainty).
1 finding from 1 review
People with fatal asthma exacerbation. · children and adults with predominantly mild to moderate asthma
1 finding from 1 review
Withdrawals (parallel group trials/first arm cross‐over trials) · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in withdrawals from trial compared with placebo (high certainty).
1 finding from 1 review
hours
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
to 72 hours (48 hours)
NSAIDs may leads to lower to 72 hours (48 hours) compared with placebo (low certainty).
1 finding from 1 review
to 7 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events
It is very uncertain whether NSAIDs changes adverse events compared with placebo (very low certainty).
1 finding from 1 review